Lakewood-Amedex Biotherapeutics (LABT) FDA Approvals $1.82 +0.04 (+2.47%) Closing price 03:58 PM EasternExtended Trading$1.80 -0.02 (-1.04%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings Lakewood-Amedex Biotherapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Lakewood-Amedex Biotherapeutics (LABT). Over the past two years, Lakewood-Amedex Biotherapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Nu-3. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Nu-3 FDA Regulatory Events Nu-3 is a drug developed by Lakewood-Amedex Biotherapeutics for the following indication: for the treatment of patients with mildly infected diabetic foot ulcers (iDFU). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Dose Update - September 24,2026Dose Update Phase 2aDrug: Nu-3Announced Date: September 24, 2026Indication: for the treatment of patients with mildly infected diabetic foot ulcers (iDFU).Announcement- Lakewood-Amedex Biotherapeutics Inc. announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of patients with mildly infected diabetic foot ulcers (iDFU).Read Announcement Lakewood-Amedex Biotherapeutics FDA Events - Frequently Asked Questions Has Lakewood-Amedex Biotherapeutics received FDA approval? As of now, Lakewood-Amedex Biotherapeutics (LABT) has not received any FDA approvals for its therapy in the last two years. What drugs has Lakewood-Amedex Biotherapeutics submitted to the FDA? In the past two years, Lakewood-Amedex Biotherapeutics (LABT) has reported FDA regulatory activity for Nu-3. What is the most recent FDA event for Lakewood-Amedex Biotherapeutics? The most recent FDA-related event for Lakewood-Amedex Biotherapeutics occurred on September 24, 2026, involving Nu-3. The update was categorized as "Dose Update," with the company reporting: "- Lakewood-Amedex Biotherapeutics Inc. announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of patients with mildly infected diabetic foot ulcers (iDFU)." What conditions do Lakewood-Amedex Biotherapeutics' current drugs treat? Currently, Lakewood-Amedex Biotherapeutics has one therapy (Nu-3) targeting the following condition: for the treatment of patients with mildly infected diabetic foot ulcers (iDFU).. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsAnnexon FDA EventsBioLineRx FDA EventsEnsysce Biosciences FDA EventsLakewood-Amedex Biotherapeutics FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsMediciNova FDA EventsSatellos Bioscience FDA EventsNuvectis Pharma FDA EventsTvardi Therapeutics FDA EventsEli Lilly and Company FDA EventsMerck & Co., Inc. FDA EventsAC Immune FDA EventsArcturus Therapeutics FDA EventsArtelo Biosciences FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies BioCardia FDA Events Passage Bio FDA Events Applied Therapeutics FDA Events BioVie FDA Events Tempest Therapeutics FDA Events Vyome FDA Events GT Biopharma FDA Events NeuroSense Therapeutics FDA Events Enlivex Therapeutics FDA Events BioLineRx FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:LABT last updated on 9/24/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakewood-Amedex Biotherapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakewood-Amedex Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dose Update - September 24,2026Dose Update Phase 2aDrug: Nu-3Announced Date: September 24, 2026Indication: for the treatment of patients with mildly infected diabetic foot ulcers (iDFU).Announcement- Lakewood-Amedex Biotherapeutics Inc. announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of patients with mildly infected diabetic foot ulcers (iDFU).Read Announcement
